Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- Registration Number
- NCT00856271
- Lead Sponsor
- Daiichi Sankyo
- Brief Summary
The purpose of this study is to evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 287
Inclusion Criteria
- mild to moderated essential hypertension (mean seated diastolic blood pressure ≥ 95 mmHg and <110 mmHg, mean seated systolic blood pressure < 180 mmHg)
- able to give written informed consent
Exclusion Criteria
- known or suspected secondary hypertension
- history of chronic hepatic diseases
- obstructive hypertrophic cardiomyopathy/clinically significant valvular heart disease
- cardiac arrhythmia
- unstable angina pectoris
- congestive heart insufficiency (New York Heart Association classification III-IV)
- bilateral renal artery stenosis
- isolated renal artery stenosis
- post renal transplantation
- history of acute myocardial infarction/percutaneous transluminal coronary angioplasty or heart surgery within three months before enrollment
- retina bleeding/effusion
- insulin dependent diabetes mellitus
- uncontrolled non-insulin dependent diabetes mellitus
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 olmesartan medoxomil olmesartan medoxomil 2 losartan potassium losartan potassium
- Primary Outcome Measures
Name Time Method Change of trough seated diastolic blood pressure from baseline to 8 weeks Baseline to 8 weeks
- Secondary Outcome Measures
Name Time Method